Allarity Therapeutics Files Proxy Statement for July 26 Meeting
Ticker: ALLR · Form: DEF 14A · Filed: Jul 1, 2024 · CIK: 1860657
Sentiment: neutral
Topics: proxy-statement, annual-meeting
TL;DR
Allarity Proxy Statement filed. Vote by July 26th.
AI Summary
Allarity Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on July 1, 2024, for its annual meeting of stockholders. The filing concerns the solicitation of proxies for the meeting, which is scheduled for July 26, 2024. The company is incorporated in Delaware and its principal executive offices are located in Boston, MA.
Why It Matters
This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming annual meeting, allowing them to make informed decisions about their votes.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain new financial or operational disclosures that would inherently increase risk.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- 0001213900-24-057937 (filing_id) — Accession Number
- 20240701 (date) — Filing Date
- 20240726 (date) — Meeting Date
- 2834 (sic_code) — Pharmaceutical Preparations
- 0001860657 (cik) — Central Index Key
- 001-41160 (sec_file_number) — SEC File Number
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information and to solicit their proxies for the annual meeting of stockholders of Allarity Therapeutics, Inc.
When is the annual meeting of stockholders scheduled to take place?
The annual meeting of stockholders is scheduled to take place on July 26, 2024.
Who is the registrant filing this proxy statement?
The registrant filing this proxy statement is Allarity Therapeutics, Inc.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Allarity Therapeutics, Inc.'s principal executive offices located?
Allarity Therapeutics, Inc.'s principal executive offices are located at 24 School St., 2nd Floor, Boston, MA 02108.
Filing Stats: 4,135 words · 17 min read · ~14 pages · Grade level 14.8 · Accepted 2024-07-01 16:47:07
Key Financial Figures
- $0.0001 — and outstanding common stock, par value $0.0001 per share, at a ratio between 1 -for-5
Filing Documents
- ea0208024-02.htm (DEF 14A) — 1795KB
- tallarity_logo.jpg (GRAPHIC) — 56KB
- tproxy_001.jpg (GRAPHIC) — 1197KB
- tproxy_002.jpg (GRAPHIC) — 1313KB
- 0001213900-24-057937.txt ( ) — 5330KB
Security Ownership of Certain Beneficial Owners and Management
Security Ownership of Certain Beneficial Owners and Management   53 Delinquent Section 16(a) Reports   53 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS   54 Transactions with Related Parties   54 Related Person Transactions Policy   56 Indemnification Agreements   57 STOCKHOLDER PROPOSALS AND DIRECTOR NOMINATIONS   58 Submission of Stockholder Nominations for Director   58 Submission of Stockholder Proposals   58 Proxy Access Director Nominations   58 Rule 14a-8   59 Mailing Instructions   59 HOUSEHOLDING   60 2023 ANNUAL REPORT   60 OTHER MATTERS   60 APPENDIX A — CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION: AUTHORIZED SHARE DECREASE   A-1 APPENDIX B — CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION: REVERSE STOCK SPLIT   B-1 APPENDIX C — AMENDED AND RESTATED 2021 EQUITY INCENTIVE PLAN   C-1 APPENDIX D — CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION: OFFICER EXCULPATION AMENDMENT   D-1 iii Table of Contents Allarity Therapeutics, Inc. 24 School Street, 2 nd Floor Boston, Massachusetts 02108 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS This 2024 proxy statement (the “Proxy Statement”) includes certain information about Allarity Therapeutics, Inc. (the “Company,” “we,” “us” or “our”), and is being solicited by our board of directors (our “Board”), in connection with our 2024 Annual Meeting of Stockholders to be held virtually on Friday, July 26, 2024 at 10:00 a.m., Eastern Time and any continuation, postponement or adjournment thereof (the “Annual Meeting”